Commercialization Resources

Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.

There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.

For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further.

The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk.

There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.

The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.

The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.

Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.

NIH Technical and Business Assistance—commonly called TABA—is designed to help SBIR and STTR recipients address product-development and commercialization needs that are often outside the core scientific aims of the award.

A Phase I award proves that NIH sees merit in the proposed technical work. It does not automatically answer the commercial questions needed for Phase II, licensing, strategic partnering, or private financing. TABA can be used to close some of those gaps.

A successful diagnostic must be technically reliable, clinically meaningful, operationally usable, economically justified, and supported by an appropriate regulatory and reimbursement strategy.

Engineering, clinical evidence, regulatory strategy, human factors, quality systems, manufacturing, reimbursement, and customer workflow all interact. Decisions made in one area can create cost or delay in another.

The objective is not to eliminate risk before financing—it is to identify which risks must be reduced before the next source of capital or strategic partner will engage.

For fundraising, that can be a costly mistake. Investors are not only evaluating whether the science is exciting.

Biotech founders sometimes assume customer discovery is less relevant because the science is complex or the product is years from market.

Regulatory clearance allows a product to be marketed. Reimbursement determines whether someone can afford to adopt it at scale.

In reality, there are two different reasons to engage a strategic partner—learning and transacting—and the timing can be different for each.